Monkeypox Overview

Save information for later
Sign Up

Learn About Monkeypox

What is the definition of Monkeypox?
Monkeypox is a rare viral infection caused by the monkeypox virus. The monkeypox virus is in the same family of viruses that cause smallpox. However, an infection with monkeypox is usually milder than smallpox.
What are the causes of Monkeypox?
Monkeypox can be contracted through skin-to-skin contact with an infected person or their body fluids, breathing in the virus through face-to-face contact, through sexual contact, touching items that were used by an infected person, from maternal-to-infant transmission during pregnancy, and bites from infected animals.
What are the symptoms of Monkeypox?
Symptoms of monkeypox usually appear three weeks after exposure to the virus. Symptoms of monkeypox vary by individual and can be mild to severe. Symptoms of monkeypox may include a rash that looks like pimples or blisters, headache, fatigue, fever, sore throat, nasal congestion, cough, chills, muscle aches, backache, and swollen lymph nodes. The rash may appear on the genitals, anus, mouth, face, chest, and hands. The pimples or blisters may be painful and itchy. The rash progresses to scabs before healing. Individuals with monkeypox remain contagious to others until all the scabs have completely healed, usually within two-to-four weeks.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Monkeypox?
Mild monkeypox infections will usually heal without treatment within two-to-four weeks. Treatment for monkeypox includes antiviral drugs such as tecovirimat, prescription mouthwashes, stool softeners, and topical gels and creams.
Who are the top Monkeypox Local Doctors?
Inger K. Damon
Elite in Monkeypox
Dr. Inger K. Damon
Infectious Disease
Elite in Monkeypox
Dr. Inger K. Damon
Infectious Disease
Atlanta, GA 
404-717-5167
Languages Spoken:
English

Inger Damon is an Infectious Disease provider in Atlanta, Georgia. Dr. Damon is rated as an Elite provider by MediFind in the treatment of Monkeypox. Her top areas of expertise are Monkeypox, Smallpox, Rabies, and Ebola Virus Disease.

Elite in Monkeypox
Elisabeth S. Pukuta
Elite in Monkeypox
Elisabeth S. Pukuta
Kinshasa, KN, CD 

Elisabeth Pukuta practices in Kinshasa, Democratic Republic of the Congo. Ms. Pukuta is rated as an Elite expert by MediFind in the treatment of Monkeypox. Her top areas of expertise are Monkeypox, Rabies, Ebola Virus Disease, and Viral Hemorrhagic Fever.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Monkeypox
Stomy S. Karhemere
Elite in Monkeypox
Stomy S. Karhemere
Kinshasa, KN, CD 

Stomy Karhemere practices in Kinshasa, Democratic Republic of the Congo. Karhemere is rated as an Elite expert by MediFind in the treatment of Monkeypox. Their top areas of expertise are Monkeypox, Rabies, Smallpox, and Chickenpox.

View All Doctors
What are the latest Monkeypox Clinical Trials?
A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects.
A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects.
Enrollment Status: Recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects

Match to trials
Find the right clinical trials for you in under a minute
Get started
Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
Enrollment Status: Recruiting
Publish Date: December 19, 2025
Intervention Type: Other
Study Phase: Not Applicable

Summary: Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or t...

View All Clinical Trials